Disease ⇒ Chronic kidney disease {40000186}

Record Keys
Type:	Disease
Parent:	[ ]
Definition:	Chronic kidney disease

Details
Initialisation date:	2020-10-13
Other Terms:	CKD

Meta Information
MedDra ID:	10064848
MedDra Level:	pt
ICD:	[ ]
Zone:	[ ]
Mechanism:	[ ]

Notes:

[ ]

Shared Reference Notes

[1.1]
- In chronic kidney disease (CKD), the “healthy” microbiota structure is disrupted, and intestinal microbes produce large quantities of uremic solutes responsible for renal damage; on the other hand, the uremic state, fueled by reduced renal clearance, causes shifts in microbial metabolism and composition, hence creating a vicious cycle in which dysbiosis and renal dysfunction are progressively worsened.
[1.2]
- Saccharibacteria (per 1-SD higher in the log-transformed abundance) could potentially decrease the concentration of serum creatinine and increase the estimated glomerular filtration rate which might help improve renal function.
[1.3] [#Uremic toxins]
[1.4]
- #Curcumin > significantly reduced plasma pro-inflammatory mediators (CCL-2, IFN-γ, and IL-4) and lipid peroxidation. - After 6 months of #Curcumin supplementation > significantly lower #Escherichia-#Shigella and significantly higher #Lachnoclostridium . - In the last 3 months of supplementation > significantly higher #Lactobacillaceae spp..
[1.5]
- Bacterial species involved in #Butyrate production, #Indole synthesis and mucin degradation were also related to CKD.
[1.6]
- Chronic kidney disease > decreased #Indole, #Indole-3-carboxaldehyde and #Indole-3-propionic acid
[1.7] [#Aging]
- #Hippuric acid has been found increased in patients with chronic kidney disease and several age-related conditions
[1.8]
[1.9]
- #Hydrogen sulfide (H2S) and methanethiol are produced during the decomposition of #Sulfur-containing amino acids, and have been linked to the progression of chronic kidney disease (CKD), cardiovascular disease, and bone metabolic disorders
- #Butyrate can protect glomerular endothelial cells against mitochondrial dysfunction.
[#Short Chain Fatty Acid] - fecal and serum SCFAs are remarkably higher in healthy controls than in patients affected by CKD. - the progression of CKD negatively correlates with the amount of #Butyrate detected in the serum of the patients. - #Butyrate supplementation might have potential beneficial effects on kidney function
- In CKD patients, the concentrations of microbiota-derived trimethylamine N-oxide (#TMAO), indoxyl #Sulfate and p-cresyl #Sulfate in the blood are increased. Because of poor renal function in CKD patients, these #Uremic toxins remain in the circulation, promote inflammation, thereby contributing to progressive kidney injury.

References Notes

[ ]

↥ Microbiota

‐ Acinetobacter Buffy coat Human [1.11]
‐ Actinomyces naeslundii Supragingival plaque Human [1.12]
‐ Actinomyces Supragingival plaque Human [1.12]
‐ Alloprevotella Stool Human [1.13]
‐ Anaerotruncus Stool Human [1.14]
‐ Bacillus Buffy coat Human [1.11]
‐ Bacteroides Stool Human [1.14]
‐ Bergeyella Supragingival plaque Human [1.12]
‐ Bifidobacterium Stool Human [1.15]
‐ Citrobacter Stool Human [1.16]
‐ Cloacibacillus Stool Human [1.14]
‐ Clostridium cluster IV Stool Human [1.13]
‐ Clostridium innocuum Stool Human [1.17]
‐ Clostridium Stool Human [1.5]
‐ Coprobacillus Stool Human [1.16]
‐ Corynebacterium Supragingival plaque Human [1.12]
‐ Deltaproteobacteria Stool Human [1.14]
‐ Desulfovibrio Stool Human [1.13]
‐ Eggerthella lenta Stool Human [1.5]
‐ Eggerthella Stool Human [1.17]
‐ Enterobacteriaceae Stool Human [1.18]
‐ Enterobacteriaceae Stool Human [1.5]
‐ Erysipelatoclostridium Stool Human [1.17]
‐ Escherichia coli Stool Human [1.18]
‐ Flavonifractor Stool Human [1.17]
‐ Hungatella Stool Human [1.19]
‐ Hyphomicrobium Buffy coat Human [1.11]
‐ Intestinimonas Stool Human [1.19]
‐ Lachnoclostridium Stool Human [1.15]
‐ Lactobacillus fermentum Supragingival plaque Human [1.12]
‐ Lactobacillus salivarius Supragingival plaque Human [1.12]
‐ Lactobacillus vaginalis Supragingival plaque Human [1.12]
‐ Lactobacillus Stool Human [1.16]
‐ Lysobacter Buffy coat Human [1.11]
‐ Marvinbryantia Stool Human [1.14]
‐ Neisseria Stool Human [1.15]
‐ Parabacteroides Stool Human [1.14]
‐ Paraprevotella Stool Human [1.14]
‐ Parasporobacterium Stool Human [1.14]
‐ Pseudarcicella Buffy coat Human [1.11]
‐ Pseudomonas Buffy coat Human [1.11]
‐ Pseudomonas Stool Human [1.19]
‐ Rothia Supragingival plaque Human [1.12]
‐ Ruminiclostridium Stool Human [1.17]
‐ Ruminococcus gnavus Stool Human [1.17]
‐ Ruminococcus torques Stool Human [1.16]
‐ Saccharibacteria Ameliorative Gut Lumen Human
‐ Scardovia wiggsiae Supragingival plaque Human [1.12]
‐ Sediminibacterium Buffy coat Human [1.11]
‐ Sellimonas Stool Human [1.17]
‐ Serratia Buffy coat Human [1.11]
‐ Shigella Stool Human [1.19]
‐ Streptococcus mitis Supragingival plaque Human [1.12]
‐ Streptococcus mutans Supragingival plaque Human [1.12]
‐ Streptococcus Stool Human [1.15]
‐ Subdoligranulum Stool Human [1.15]
‐ Weissella Stool Human [1.17]
‐ Yersinia Buffy coat Human [1.11]

↧ Microbiota

‐ Aanaerobacter Stool Human [1.14]
‐ Akkermansia Stool Human [1.13]
‐ Alcaligenaceae Stool Human [1.14]
‐ Bacteroides eggerthii Stool Human [1.5]
‐ Bacteroides fragilis Stool Human [1.14]
‐ Bacteroides Stool Human [1.15]
‐ Barnesiella Stool Human [1.14]
‐ Bifidobacterium Stool Human [1.14]
‐ Butyricicoccus Stool Human [1.14]
‐ Candidatus Buffy coat Human [1.11]
‐ Carnobacterium Stool Human [1.17]
‐ Catenibacterium Stool Human [1.14]
‐ Clostridium coccoides group Stool Human [1.14]
‐ Clostridium Stool Human [1.14]
‐ Collinsella Stool Human [1.17]
‐ Coprococcus Stool Human [1.14]
‐ Corynebacterium Buffy coat Human [1.11]
‐ Dialister Stool Human [1.14]
‐ Dorea Stool Human [1.14]
‐ Enterobacter Stool Human [1.15]
‐ Enterococcus Stool Human [1.14]
‐ Escherichia coli Stool Human [1.14]
‐ Eubacterium coprostanoligenes Stool Human [1.17]
‐ Eubacterium hallii Stool Human [1.17]
‐ Eubacterium rectale Stool Human [1.17]
‐ Faecalibacterium prausnitzii Stool Human [1.16]
‐ Faecalibacterium Stool Human [1.14]
‐ Hallella Stool Human [1.14]
‐ Lachnospira Stool Human [1.17]
‐ Megamonas Stool Human [1.19]
‐ Oribacterium Stool Human [1.14]
‐ Paracoccus Buffy coat Human [1.11]
‐ Parasutterella Stool Human [1.14]
‐ Pasteurellaceae Stool Human [1.14]
‐ Prevotellaceae Stool Human [1.19]
‐ Prevotella Stool Human [1.5, 1.14]
‐ Pseudomonadales Stool Human [1.14]
‐ Pseudomonas Stool Human [1.14]
‐ Pyramidobacter Stool Human [1.19]
‐ Rikenellaceae Stool Human [1.19]
‐ Romboutsia Stool Human [1.17]
‐ Roseburia faecis Stool Human [1.5]
‐ Roseburia Stool Human [1.20]
‐ Ruminococcaceae Stool Human [1.19]
‐ Ruminococcus Stool Human [1.17]
‐ Shigella Stool Human [1.15]
‐ Slackia Stool Human [1.14]
‐ Sphingomonas Buffy coat Human [1.11]
‐ Stenotrophomonas Buffy coat Human [1.11]
‐ Streptococcus Stool Human [1.18]
‐ Subdoligranulum Stool Human [1.17]
‐ Tyzzerella Buffy coat Human [1.11]
‐ Tyzzerella Stool Human [1.17]

Impact by Microbiota

[ ]

↥ Metabolome

‐ Creatinin Deteriorative

↧ Metabolome

[ ]

Impact by Metabolome

[ ]

Related Factor

‐ Curcumin [1.4]

Subclass

[ ]

References

[ ]

Author: MetaBiom
Identifier: 40000186
URL: https://www.metabiom.org/disease/86/chronic-kidney-disease
Keywords: Microbiome, Dysbiosis, Chronic

Common References

[1.1] Intestinal microbiota and diabetic kidney diseases: role of microbiota and derived metabolites in the modulation of renal inflammation and disease progression [2021] [Review] [ScienceDirect] [Journal] [80001512]
[1.2] The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for complex human diseases [2020] [Review] [Microbiome] [Journal] [80000204]
[1.3] Gut Microbiota and Their Derived Metabolites, a Search for Potential Targets to Limit Accumulation of Protein-Bound Uremic Toxins in Chronic Kidney Disease [2021] [Research] [Toxins] [Journal] [80002131]
[1.4] Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease [2022] [Research] [Nutrients] [Journal] [80002204]
[1.5] Microbiome in Chronic Kidney Disease (CKD): An Omics Perspective [2022] [Review] [Toxins] [Journal] [80002388]
[1.6] Small molecules in the big picture of gut microbiome-host cross-talk - IMPORTANT [2022] [Review] [EBioMedicine] [Journal] [80002422]
[1.7] The plasma metabolome of long COVID patients two years after infection [2023] [Study] [Scientific Reports] [Journal] [80003227]
[1.8] Gut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease [2023] [Seminars in Nephrology] [Journal] [80003293]
[1.9] A review of the interaction between diet composition and gut microbiota and its impact on associated disease [2024] [Review] [Journal of Future Foods] [Journal] [80003491]
[1.10] Sodium Butyrate as Key Regulator of Mitochondrial Function and Barrier Integrity of Human Glomerular Endothelial Cells [2023] [International journal of molecular sciences] [Journal] [80003560]
[1.11] Blood microbiome profile in CKD: A pilot study [2019] [Clinical Journal of the American Society of Nephrology] [Journal] [80000967]
[1.12] Carious status and supragingival plaque microbiota in hemodialysis patients [2018] [PLOS ONE] [Journal] [80000880]
[1.13] Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease [2019] [Frontiers in Cellular and Infection Microbiology] [Journal] [80001140]
[1.14] Alteration of the gut microbiota in Chinese population with chronic kidney disease [2017] [Scientific Reports] [Journal] [80000616]
[1.15] Dysbiosis of the gut microbiome is associated with CKD5 and correlated with clinical indices of the disease: a case-controlled study [2019] [Journal of Translational Medicine] [Journal] [80001101]
[1.16] Gut microbiota composition and frailty in elderly patients with Chronic Kidney Disease [2020] [PLOS ONE] [Journal] [80001402]
[1.17] Altered gut microbiota and microbial biomarkers associated with chronic kidney disease [2018] [MicrobiologyOpen] [Journal] [80000867]
[1.18] Isolation and quantification of uremic toxin precursor-generating gut bacteria in chronic kidney disease patients [2020] [International journal of molecular sciences] [Journal] [80001379]
[1.19] Characterizing the gut microbiota in patients with chronic kidney disease [2020] [Abstract] [Postgraduate Medicine] [Journal] [80001316]
[1.20] A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression [2016] [Antonie van Leeuwenhoek (2016)] [Journal] [80000548]

MetaBiom uses only essential session cookies to give you a perfect experience on the website. By selecting "Accept essential Cookies" you agree the use of these cookies.

Disease ⇒ Chronic kidney disease {40000186}

Record Keys

Details

Meta Information

Notes:

Shared Reference Notes

References Notes

Common References